Tune Therapeutics Enters Clinical Arena with TUNE-401: A Novel Epigenetic Silencer Targeting Hepatitis B.

Disitamab Vedotin is an antibody-drug conjugate (ADC) developed by Hengrui Medicine, targeting human epidermal growth factor receptor 2 (HER2).

Tirzepatide treatment in obese or overweight adults with pre-diabetes led to lasting weight reduction, with almost 99% staying free of diabetes after 176 weeks.

PLX-4545 is a molecular glue drug developed by Plexium, Inc. The drug targets IKZF2 and is intended for the treatment of neoplasms.

MoonLake Immunotherapeutics has launched Phase 3 of the IZAR program for the Nanobody® sonelokimab in individuals suffering from active psoriatic arthritis.

Mipomersen, developed by Isis Pharmaceuticals and marketed by Genzyme, is an antisense oligonucleotide that targets the apolipoprotein B-100 (ApoB-100) mRNA.

Gan & Lee Pharmaceuticals reported favorable Phase 1 outcomes for its oral GLP-1 receptor agonist, GZR18 tablet, in healthy subjects, showing a weight loss of 4.16% over two weeks.

Omaveloxolone is a small molecule drug developed by Reata Pharmaceuticals, Inc. that targets the Nrf2 protein.

Pimicotinib meaningfully enhanced results for patients with tenosynovial giant cell tumor in an international Phase III study.

Brentuximab Vedotin, also known as Adcetris, is an antibody-drug conjugate (ADC) developed by Seattle Genetics and Takeda Pharmaceutical Company.

New BLA for Datopotamab Deruxtecan filed in the U.S. for fast-track approval in patients with advanced EGFR-mutated non-small cell lung cancer who have received prior treatment.

Palbociclib was first approved in the United States in February 2015 and has since been approved in other countries around the world.